Quick Answer
HCW Biologics Inc. reported Operating Income Loss of -$13.16 million for the year ending 2025.
- HCW Biologics Inc. showed an increase of +55.3% in Operating Income Loss from 2024 to 2025.
- This data is from HCW Biologics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), HCW Biologics Inc.'s Operating Income Loss has declined by 126.0%.
- Historical annual values: Fiscal year 2025: -$13.16 million | Fiscal year 2024: -$29.46 million | Fiscal year 2023: -$25.72 million | Fiscal year 2022: -$15.08 million | Fiscal year 2021: -$13.37 million | Fiscal year 2020: -$5.82 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: